BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel

01 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

BioNTech Strengthens Manufacturing Capabilities with First In-House Plasmid DNA Manufacturing Facility

02 Feb 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development

10 Jan 2023 07:15:00 By Nasdaq GlobeNewswire

BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030

05 Jan 2023 19:01:00 By Nasdaq GlobeNewswire

BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference

28 Dec 2022 06:45:00 By Nasdaq GlobeNewswire

BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

23 Dec 2022 03:00:00 By Nasdaq GlobeNewswire

BioNTech and Fosun Pharma Provide COVID-19 Vaccine Doses For Vaccination of German Expatriates in China

22 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Update on First BioNTainer for African-based mRNA Manufacturing Facility

21 Dec 2022 08:45:00 By Nasdaq GlobeNewswire

BioNTech Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

21 Dec 2022 06:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

09 Dec 2022 06:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

08 Dec 2022 10:39:34 By Nasdaq GlobeNewswire

BioNTech and Ryvu Therapeutics Enter into Global Collaboration to Develop and Commercialize Immuno-Modulatory Small Molecule Candidates

30 Nov 2022 01:02:35 By Nasdaq GlobeNewswire

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

18 Nov 2022 06:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

16 Nov 2022 18:30:00 By Nasdaq GlobeNewswire

BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore

13 Nov 2022 20:30:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

10 Nov 2022 09:45:00 By Nasdaq GlobeNewswire

BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update

07 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

04 Nov 2022 06:48:48 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

12 Oct 2022 10:30:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron

25 Jun 2022 10:02:16 By Nasdaq GlobeNewswire